Study to Compare Efficacy and Safety of Daptomycin in Elderly Patients With Complicated Skin and Soft Tissue Infections

Infections Clinical Trial

Official title:

An Open Label, Multi-center, Randomized, Comparative Phase IIIb Study to Compare Efficacy and Safety of Intravenous (i.v.) Daptomycin With That of Semi-Synthetic Penicillins (SSPs) or Vancomycin in the Treatment of Elderly Patients (Aged ≥ 65 Years) With Complicated Skin and Soft Tissue Infections (cSSTI)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01184872
• Other study ID #: CCBC134A2404
• Secondary ID: 2009-014391-22
• Status: Completed
• Phase: Phase 3
• First received: February 18, 2010
• Last updated: July 9, 2012
• Start date: March 2010
• Est. completion date: March 2011

Study information

• Verified date: July 2012
• Source: Novartis
• Contact: n/a
• Is FDA regulated: No
• Health authority: Austria: Agency for Health and Food SafetyGermany: German Institute of Medical Documentation and InformationItaly: Ethics CommitteeSpain: Comité Ético de Investigación ClínicaDominican Republic: Secretaría del Estado de Salud Pública y Asistencia Social (SESPAS)Russia: FSI Scientific Center of Expertise of Medical Application
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to provide data documenting the efficacy of daptomycin in elderly patients aged ≥ 65 years with complicated Skin and Soft Tissue Infections.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 120
• Est. completion date: March 2011
• Est. primary completion date: March 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 65 Years and older

Eligibility

Inclusion criteria:

Patients 65 years or older with infection of sufficient severity to require in-patient hospitalization, with parenteral antimicrobial therapy for at least 96 hours.

Patients who have a diagnosis of Gram-positive complicated Skin and Soft Tissue Infections (cSSTIs) with or without bacteremia:

• Wound infections,

• Major abscesses with or without recognized preceding trauma, that require antibiotic therapy in addition to surgical incision and drainage,

• Severe carbunculosis,

• Infected ulcers (except patients with multiple infected ulcers) associated with:

diabetes, vascular insufficiency, pressure (i.e., decubitus ulcers).

Exclusion criteria:

Conditions requiring surgery that in and of itself would cure the infection or remove the infected site (e.g., amputation).

Minor or superficial skin infections (e.g., furuncles, simple abscesses, acne, impetigo).

Cellulitis, including erysipelas, not associated with complicating factors. However, patients with cellulitis associated with more serious infection (e.g., surgical wound, diabetic ulcer, deep tissue) can be enrolled (proportion of these patients will be limited to 30%).

Infections for which outcome is difficult to assess:

• Perirectal abscess,

• Hidradenitis suppurativa,

• Gangrene,

• Infected human or animal bites,

• Multiple infected ulcers at distant sites,

• Infected burns (only third degree burn wound or wound area of more than 10 cm diameter),

• Conditions requiring emergency surgery including necrotizing fasciitis.

Medical conditions:

• History of significant allergy or intolerance to Vancomycin or Daptomycin. Hypersensitivity to SSPs penicillins is not an exclusion criterion,

• Concomitant clinically suspected or confirmed other site of infection or disorder at study entry that may interfere with the evaluation in this protocol,

• Infections associated with a permanent prosthetic device that will not be removed within 24 hours after enrolment,

• Known or suspected HIV infection with a CD4+ T-cell count < 500/µL (HIV testing is not required),

• Severe hepatic disease (Child-Pugh Class C) or ALT and/or AST > 5 times ULN and/ or total bilirubin > 2 times ULN at screening,

• Calculated creatinine clearance by the Cockcroft-Gault equation using actual body weight < 30 mL/min or any type of dialysis,

• Treatment with any investigational agent or device within 30 days of study drug administration.

Exclusion criteria related to medications:

• Previous systemic antibacterial therapy for the treatment of Gram-positive complicated skin and soft tissue infections for more than 24 hours within 48 hours prior to the day of first infusion of study drug unless:

• The previous antibacterial therapy was administered for 3 or more calendar days with either worsening or no improvement in the clinical signs and symptoms of cSSTIs, and was not Vancomycin or SSPs.

Other protocol-defined inclusion/exclusion criteria applied.

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Communicable Diseases
• Infection
• Infections
• Soft Tissue Infections

Intervention

Drug:
• Daptomycin
Patients with bacteremia: Daptomycin 6 mg/Kg intravenous once daily for at least 5 days and up to 28 days. Patients without bacteremia: Daptomycin 4 mg/Kg intravenous once daily for at least 5 days and up to 14 days.
• Vancomycin or Semi-Synthetic Penicillins (SSPs)
Patients with bacteremia: Vancomycin 1 g intravenous twice daily or Semi-Synthetic Penicillins 2 g intravenous every 4 hours for at least 5 days and up to 28 days. Patients without bacteremia: Vancomycin 1 g intravenous twice daily or Semi-Synthetic Penicillins 2 g intravenous every 6 hours for at least 5 days and up to 14 days.

Locations

Country	Name	City	State
Austria	Novartis Investigative Site	Graz
Austria	Novartis Investigative Site	Vienna
Germany	Novartis Investigative Site	Bochum
Germany	Novartis Investigative Site	Essen
Germany	Novartis Investigative Site	Homburg
Germany	Novartis Investigative Site	Magdeburg
Germany	Novartis Investigative Site	Mannheim
Germany	Novartis Investigative Site	Muenster
Germany	Novartis Investigative Site	Tuebingen
Italy	Novartis Investigative Site	Pisa
Russian Federation	Novartis Investigative Site (1)	Moscow
Russian Federation	Novartis Investigative Site	Novosibirsk
Russian Federation	Novartis Investigative Site (2)	Saint Petersburg
Russian Federation	Novartis Investigative Site	Yaroslavi
Spain	Novartis Investigative Site (1)	Madrid
Spain	Novartis Investigative Site	Santander
Spain	Novartis Investigative Site	Seville

Sponsors (1)

Lead Sponsor	Collaborator
Novartis Pharmaceuticals

Countries where clinical trial is conducted

Austria,  Germany,  Italy,  Russian Federation,  Spain, 

References & Publications (1)

Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI; Daptomycin 98-01 and 99-01 Investigators. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004 Jun 15;38(12):1673-81. Epub 2004 May 20. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Patients With Clinical Success at the Test-Of-Cure (TOC) Visit	Success: Clinically significant signs and symptoms associated with the skin infection present at the pre-treatment infection site resolved (cure), or improved without need of further antibacterial therapy. Failure: Persistence or progression of signs and symptoms or development of new clinical signs and symptoms at the infection site, or concomitant antibacterial therapy with activity against isolated organisms, or treatment duration longer than pre-specified, or switch back to intravenous therapy due to relapse, or requirement of a major surgical procedure as adjunct or follow-up therapy.	Baseline and 7 to 14 days after end of therapy	No
Secondary	Number of Participants With Microbiological Response at Test-of-Cure (TOC) Visit	Microbiological Success: All infecting Gram-positive pathogens isolated at baseline were eradicated or presumed to be eradicated at the Test-of-Cure (TOC) evaluation and a super infecting pathogen was not isolated either prior to or at the TOC evaluation. Microbiological Failure: Persistence or relapse / re-infection of one or more infecting Gram-positive pathogens or isolation of a super infecting pathogen prior to or at the TOC evaluation.	Baseline and 7 to 14 days after end of therapy	No
Secondary	Duration of Treatment (Intravenous)	Duration of treatment is the interval from first to last intravenous (i.v.) administration. It was preferable that a patient complete the whole antibiotic treatment with the randomized i.v. study drug only. Duration of treatment in patients with bacteremia could be extended up to 28 days.	Up to 28 days	No
Secondary	Duration of Treatment (Intravenous and Oral)	Duration of treatment is the interval from first to last intravenous (i.v.) or to last oral administration if patients switched to an oral antibiotic therapy. It was preferable that a patient complete the whole antibiotic treatment with the randomized i.v. study drug only. Duration of treatment in patients with bacteremia could be extended up to 28 days.	Up to 28 days	No
Secondary	Number of Patients With Adverse Events, Serious Adverse Events and Death		Continuously from baseline up to 28 days after end of antibiotic treatment.	Yes